Abstract: FR-PO231
Pretreatment Extracellular Volume Expansion Predicts Body Fluid Response to SGLT2 Inhibitor in Diabetic Kidney Disease
Session Information
- Diabetic Kidney Disease: Advancing Treatment
November 08, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Diabetic Kidney Disease
- 602 Diabetic Kidney Disease: Clinical
Authors
- Ohara, Ken, Jichi Medical University, Shimotsuke, TOCHIGI, Japan
- Masuda, Takahiro, Jichi Medical University, Shimotsuke, TOCHIGI, Japan
- Morinari, Masato, Nasu Minami Hospital, Nasukarasuyama, TOCHIGI, Japan
- Okada, Mari, Jichi Medical University Hospital, Shimotsuke, Japan
- Miki, Atsushi, Jichi Medical University, Shimotsuke, TOCHIGI, Japan
- Nakagawa, Saki, Jichi Medhical University, Shimotsuke, Tochigi, Japan
- Murakami, Takuya, Jichi Medical University, Shimotsuke, Tochigi, Japan
- Oka, Kentaro, Jichi Medical University, Shimotsuke, TOCHIGI, Japan
- Asakura, Maki, Jichi Medical University, Shimotsuke, TOCHIGI, Japan
- Miyazawa, Yasuharu, Nasu-Minami Hospital, Nasukarasuyama, Japan
- Maeshima, Akito, Jichi Medical University, Shimotsuke, TOCHIGI, Japan
- Akimoto, Tetsu, Department of Nephrology, Jichi Medical University, Shimotsuke, Japan
- Saito, Osamu, Jichi Medical University, Shimotsuke, TOCHIGI, Japan
- Nagata, Daisuke, Jichi Medical University, Shimotsuke, TOCHIGI, Japan
Background
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are an antihyperglycemic drug with diuretic action. We recently reported that SGLT2 inhibitor dapagliflozin ameliorates extracellular volume expansion with a mild increase in urine volume (Nephrology 2018). However, the predictors of fluid response to SGLT2 inhibitors remain unclear.
Methods
Thirty diabetic kidney disease (DKD) patients were treated with dapagliflozin (5mg/day). Body fluid volume including intracellular water (ICW), extracellular water (ECW) and total body water (TBW) was measured on days 0 and 7 using a bioimpedance analysis (BIA) device (InBody S10). Patients were divided into low and high responders by the median value of change in the ECW/TBW for 1 week, which is a marker of extracellular volume expansion. Baseline clinical parameters were compared between the low and high responders.
Results
The body weight significantly decreased (68.0±2.8 vs. 63.0±3.2 kg, p<0.001), but the estimated glomerular filtration rate (eGFR) was not significantly changed (29.2±2.7 vs. 26.1±2.3 mL/min/1.73 m2, p=0.143) after 1 week. BIA showed that the median value of the change in the ECW/TBW for 1 week was -1.2% (0.416±0.005 vs. 0.400±0.012, p=0.054). The ECW (high responders 17.0±1.2 vs. low responders 14.2±1.2 L, p=0.056), the TBW (39.8±2.6 vs. 34.8±2.6 L, p=0.093), the ECW/TBW (0.426±0.001 vs. 0.406±0.001, p=0.021) and serum brain natriuretic peptide (318±53 vs. 92±50 pg/mL, p=0.003) in the high responders were higher than in the low responders. The eGFR (24.5±3.6 vs. 33.3±3.6 mL/min/1.73 m2, p=0.046) and serum albumin level (2.9±0.2 vs. 3.4±0.2 g/dL, p=0.075) in the high responders were lower than in the low responders. Significant partial correlations adjusted for the eGFR were observed between the baseline ECW/TBW and changes in the ECW/TBW (r=-0.469, p=0.009) and the TBW (r=-0.528, p=0.027).
Conclusion
Extracellular volume expansion predicts body fluid response to SGLT2 inhibitor dapagliflozin in DKD patients. This result suggests that SGLT2 inhibitor may change its diuretic action depending on the pretreatment extracellular volume status.
Funding
- Private Foundation Support